Appointment dossier — Ovarian Carcinosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Carcinosarcoma
- Carboplatin — Human evidence · 1 positive · PMID 35007153
- Ifosfamide — Human evidence · 1 positive · PMID 35007153
- Paclitaxel — Human evidence · 1 positive · PMID 35007153
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT03651206 · Phase 2 / Phase 3 — Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (France)
- NCT05619913 · Phase 2 — EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (Australia)
- NCT05920798 · Phase 1 / Phase 2 — Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (United States)
- NCT06639074 · Phase 2 — Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (United States)
- NCT04919629 · Phase 2 — APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (United States)
- NCT05902988 · Phase 1 / Phase 2 — A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (United States)
- NCT06483048 · Phase 1 — MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (United States)
- NCT03686124 · Phase 1 / Phase 2 — ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (United States)
- NCT06638931 · Phase 2 — Agnostic Therapy in Rare Solid Tumors (Brazil)
- NCT04657068 · Phase 1 / Phase 2 — A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (United States)
- NCT06730347 · Phase 2 — A Study of Lorigerlimab in Participants With Advanced Solid Tumors (United States)
- NCT06399757 · Phase 1 / Phase 2 — A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (United States)
- NCT05238922 · Phase 1 — Study of INCB123667 in Subjects With Advanced Solid Tumors (United States)
- NCT05005403 · Phase 1 — Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (United States)
- NCT05799274 · Phase 1 — Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors (United States)
- NCT06508307 · Phase 1 — A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors (China)
- NCT06451497 · Phase 1 — This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (United States)
- NCT07326111 · Phase 4 — A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese (Germany)
Most-relevant first: trials that name Ovarian Carcinosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Has my tumor been tested for p53, and would the result open up targeted treatments or trials?
- Has my tumor been tested for ER/PR, and would the result open up targeted treatments or trials?
- Has my tumor been tested for BRCA1/2 / HRD, and would the result open up targeted treatments or trials?
- I've read that Carboplatin has been studied in people for Ovarian Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Ifosfamide has been studied in people for Ovarian Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Paclitaxel has been studied in people for Ovarian Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT03651206), am I eligible for any — here or at a larger cancer center?
- Is my tumor epithelial-dominant, sarcoma-dominant, or truly mixed — and how does that affect treatment options?
- How aggressive is my specific case based on stage, grade, and pathology markers?
- What is my likely prognosis, and how do factors like BRCA/HRD or complete cytoreduction influence survival?
- Can cytoreductive surgery be complete (R0) or optimal in my case, and what risks are involved?
- Should I seek surgery at a high-volume center experienced in ovarian carcinosarcoma?
- If surgery is not possible, what other disease-control strategies are available?
- If chemo is planned, which regimen is best for me — platinum/taxane (epithelial-leaning) or anthracycline/ifosfamide (sarcoma-leaning)?
- How many cycles of chemotherapy are recommended, and what is the expected benefit?
- What are the most common side effects of these regimens, and how are they managed?
- If I become resistant to platinum, what other systemic therapies could be considered?
- Have my tumor and blood been tested for BRCA, HRD, MSI/MMR, PD-L1, and HER2?
- If I have BRCA or HRD, would a PARP inhibitor be an option?
- If PD-L1 positive, could I qualify for immunotherapy or a clinical trial?
- Are there other molecular alterations (like p53, PI3K/AKT/mTOR, CLDN18.2) that could influence future treatment?
- Which clinical trials are available for ovarian carcinosarcoma or mixed Müllerian tumors?